YolTech Therapeutics Raises $70 Million in Series C Financing

SHANGHAI – May 29, 2026 – YolTech Therapeutics, a late clinical-stage biotechnology company developing in vivo gene-editing therapies, today announced the closing of its approximately $70 million Series C financing led by Loyal Valley Capital. The proceeds will be used to advance the Company’s core clinical pipelines and accelerate its global clinical development and commercial readiness.

“We are delighted to back YolTech Therapeutics as a lead investor,” said Loyal Valley Capital. “The company has made remarkable progress advancing its in vivo gene-editing platform and clinical pipeline. We share its mission to bring breakthrough therapies to patients worldwide and support its global development and growth.”

“We greatly appreciate the support from Loyal Valley Capital, our new investors and existing shareholders,” said Yuxuan Wu, Co-Founder and CEO of YolTech Therapeutics. “This financing will enable us to further advance our clinical-stage programs and expand our global development efforts. We are focused on delivering high-quality clinical data and unlocking the potential of our in vivo gene-editing platform to bring transformative treatment options to patients.”

About YolTech

Built on HEPDONE™ Novel Editor Platform and non-viral LNP technologies, YolTech Therapeutics is advancing in vivo gene-editing medicines with the potential for a one-time treatment that provides lifelong benefit. The company’s expanding clinical pipeline addresses genetic, metabolic, cardiovascular, and autoimmune diseases, with early clinical results supporting the potential for durable and transformative outcomes.